Operator

Hello, and welcome to the Edgewise Therapeutics Update Call. [Operator Instructions] As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I would now like to pass the call over to Michael Nofi, Edgewise CFO. Please proceed.

Michael Nofi
Chief Financial Officer

Thank you, and good morning. Welcome to the Edgewise Therapeutics conference call to discuss our top line data of EDGE-7500 from the Phase II CIRRUS-HCM Part D 12-week trial in individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. This morning, we issued a press release, which outlines these results. You can access the press release as well as the slides that we will be presenting today by going to the Investors and News section of our website at www.edgewisetx.com. A replay of the event will also be available as a webcast on our website.

Joining me today are Dr. Kevin Koch, Chief Executive Officer; Dr. Behrad Derakhshan, Chief Operating Officer; Dr. Aylin Tugcu, Senior Vice President, Cardiovascular Clinical Development and Medical Affairs; Dr. Michael Ayers, Director of the HCM Center of Excellence at the University of Virginia and EDGE-7500 Clinical Program Lead; and Dr. Chris Duton, Senior Vice President, Cardiovascular